About Pheno

Developing remyelinating therapies for the unmet need for a neuroprotective therapy for Multiple Sclerosis.
Learn More

Pheno Therapeutics is a new biotechnology company founded by the University of Edinburgh and Advent Life Sciences that builds on the ground breaking research of Profs Siddharthan Chandran and Neil Carragher, world class experts in multiple sclerosis and stem cell biology, and phenotypic screening, respectively.

Dr. Jon Moore

Dr. Jon Moore is CEO and is also an Operating Partner at Advent Life Sciences. Jon has >25 years of experience in Life Sciences starting with postdoctoral work in molecular motors & cell cycle control including a period with Nobel Prize winner Tim Hunt, followed by 10 years small molecule drug discovery experience at Vernalis. More recently Jon was CSO of Horizon Discovery where he helped established the companies world-leading capabilities for using CRISPR/Cas9 in target ID and validation and co-founded Avvinity Therapeutics. Jon holds a Ph.D. from the University of Newcastle upon Tyne and was published >40 peer-reviewed papers.

Prof. Siddarthan Chandran

Prof. Siddarthan Chandran is Head of Dept of Neurology at Edinburgh University and leads the Anne Rowling Regenerative Neurology Clinic. Siddharthan is a word class clinician and experienced in conducting early stage trials on novel remyelinating drugs. He is one of the co founders of Pheno Therapeutics, is expert in the use of human iPSCs to model neurological disorders and has published >100 peer reviewed papers.

Prof. Neil Carragher

Prof. Neil Carragher is a phenotypic screening pioneer & thought leader. He has extensive industry experience with Yamanouchi Pharmaceuticals & AstraZeneca and as Director of Edinburgh Cancer Discovery Unit and leads Edinburgh Phenotypic Assay Centre as well as being Chief Scientist for the UK Phenotypic Screening Centre with over 70 peer reviewed papers.